Boston Scientific to acquire Augmenix for $500M

Boston Scientific has entered a definitive agreement to acquire Augmenix, developer of the SpaceOAR System for prostate cancer radiotherapy, for an upfront cash payment of $500 million plus up to $100 million in sales-based milestones.

“The acquisition furthers our category leadership strategy in urology and the SpaceOAR hydrogel is a crucial addition to our growing prostate health treatment portfolio.”news.bostonscientific.com

• 2 sources
• news.bostonscientific.comBoston Scientific Announces Agreement To Acquire Augmenix, Inc.Sep 6, 2018
• massdevice.comBoston Scientific closes $600m Augmenix buyout - MassDeviceBrad PerrielloOct 17, 2018

Summarized from public sources; check the original articles before acting on it.